X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (569) 569
rosuvastatin calcium (562) 562
male (400) 400
index medicus (357) 357
fluorobenzenes - therapeutic use (353) 353
female (350) 350
sulfonamides - therapeutic use (330) 330
pyrimidines - therapeutic use (329) 329
fluorobenzenes - adverse effects (306) 306
middle aged (288) 288
rosuvastatin (283) 283
sulfonamides - adverse effects (282) 282
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (281) 281
pyrimidines - adverse effects (281) 281
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (259) 259
aged (225) 225
statins (221) 221
fluorobenzenes - administration & dosage (189) 189
atorvastatin (170) 170
pyrimidines - administration & dosage (170) 170
sulfonamides - administration & dosage (170) 170
treatment outcome (160) 160
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (147) 147
cholesterol (137) 137
pharmacology & pharmacy (137) 137
adult (134) 134
cardiac & cardiovascular systems (123) 123
medicine, general & internal (116) 116
cholesterol, ldl - blood (113) 113
atorvastatin calcium (108) 108
fluorobenzenes - pharmacology (106) 106
hypercholesterolemia - drug therapy (102) 102
animals (101) 101
simvastatin (93) 93
dose-response relationship, drug (90) 90
drug therapy (86) 86
sulfonamides - pharmacology (80) 80
pyrimidines - pharmacology (79) 79
double-blind method (77) 77
risk factors (77) 77
abridged index medicus (74) 74
heptanoic acids - therapeutic use (74) 74
pravastatin (74) 74
pyrroles - therapeutic use (73) 73
c-reactive protein (69) 69
coronary-heart-disease (69) 69
lipids (69) 69
risk (69) 69
cardiovascular disease (68) 68
time factors (67) 67
cardiovascular diseases - prevention & control (66) 66
atherosclerosis (65) 65
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (65) 65
prevention (65) 65
fluorobenzenes - pharmacokinetics (63) 63
hypercholesterolemia (63) 63
safety (62) 62
drug therapy, combination (61) 61
dyslipidemias - drug therapy (59) 59
aged, 80 and over (56) 56
cardiovascular (56) 56
drug interactions (56) 56
heptanoic acids - adverse effects (56) 56
pyrroles - adverse effects (56) 56
anticholesteremic agents - therapeutic use (55) 55
density-lipoprotein cholesterol (54) 54
efficacy (54) 54
statin therapy (54) 54
antilipemic agents (52) 52
research (52) 52
prospective studies (51) 51
hyperlipidemias - drug therapy (50) 50
statin (50) 50
dosage and administration (49) 49
rats (49) 49
biomarkers - blood (48) 48
cholesterol - blood (46) 46
heptanoic acids - administration & dosage (46) 46
myocardial-infarction (46) 46
pyrimidines - pharmacokinetics (46) 46
pyrroles - administration & dosage (46) 46
sulfonamides - pharmacokinetics (46) 46
care and treatment (45) 45
cholesterol, hdl - blood (44) 44
randomized controlled trials as topic (44) 44
therapy (44) 44
follow-up studies (43) 43
pharmacokinetics (43) 43
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (42) 42
hypercholesterolemia - blood (42) 42
triglycerides - blood (42) 42
disease (41) 41
nutritional and metabolic diseases (41) 41
rhabdomyolysis - chemically induced (41) 41
simvastatin - therapeutic use (40) 40
anticholesteremic agents - adverse effects (39) 39
lipids - blood (39) 39
medicine, research & experimental (39) 39
cardiology (38) 38
dyslipidemia (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (610) 610
German (7) 7
Russian (5) 5
Spanish (4) 4
Chinese (3) 3
Italian (3) 3
Dutch (2) 2
French (2) 2
Czech (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | INTRAVASCULAR ULTRASOUND | RANDOMIZED CONTROLLED-TRIAL | AVERAGE CHOLESTEROL LEVELS | ROSUVASTATIN | ARTERY-DISEASE | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Ultrasonography | Atorvastatin | Heart diseases | Lipoproteins (high density) | Statins
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1395 - 1407
In a multicenter, randomized trial, 2776 patients undergoing maintenance hemodialysis who were not currently taking a statin were randomly assigned to... 
CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | DIALYSIS PATIENTS | STATIN THERAPY | HEART-FAILURE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | RENAL-TRANSPLANT RECIPIENTS | ATORVASTATIN | Kidney Failure, Chronic - mortality | Prospective Studies | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Treatment Failure | Aged, 80 and over | Cardiovascular Diseases - mortality | Female | C-Reactive Protein - analysis | Double-Blind Method | Kidney Failure, Chronic - drug therapy | Kaplan-Meier Estimate | Rosuvastatin Calcium | Kidney Failure, Chronic - therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Kidney Failure, Chronic - blood | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Renal Dialysis - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Prevention | Usage | Care and treatment | Hemodialysis | Mortality | Rosuvastatin | Cardiovascular diseases | Health aspects | Cardiovascular disease | Heart attacks | Drug therapy | Metabolic disorders | Cholesterol | Statins | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | C-Reactive Protein | MEDICIN OCH HÄLSOVETENSKAP | Kidney Failure | 80 and over | Pyrimidines | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | therapy | Fluorobenzenes | prevention & control | analysis | blood | Chronic | Sulfonamides | mortality | adverse effects | therapeutic use | Kaplan-Meiers Estimate | Renal Dialysis
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 3/2013, Volume 346, Issue 7900, pp. 14 - 14
Objective To quantify an association between acute kidney injury and use of high potency statins versus low potency statins.Design Retrospective observational... 
RESEARCH | Observational research | Databases | Kidneys | Medication administration | Acute kidney injury | Database administration | Hospital admissions | Hospitalization | Kidney diseases | WOMEN | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CHOLESTEROL | DISEASE | MEN | OUTCOMES | VALIDITY | FAILURE | ROSUVASTATIN | Simvastatin - therapeutic use | United States - epidemiology | Confidence Intervals | Simvastatin - adverse effects | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Heptanoic Acids - adverse effects | Hypercholesterolemia - drug therapy | Incidence | Dose-Response Relationship, Drug | Patient Safety | Pyrroles - adverse effects | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Odds Ratio | Pyrroles - therapeutic use | British Columbia - epidemiology | Databases, Factual | Drug Administration Schedule | Risk Assessment | Rosuvastatin Calcium | Logistic Models | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypercholesterolemia - diagnosis | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Acute Kidney Injury - epidemiology | United Kingdom - epidemiology | Fluorobenzenes - therapeutic use | Cohort Studies | Medical research | Patient admissions | Statins | Risk factors | Injuries
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9841, pp. 565 - 571
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 22, pp. 2248 - 2261
In this clinical trial, rosuvastatin was compared with placebo in elderly patients with systolic, ischemic heart failure. Although rosuvastatin significantly... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | DESIGN | THERAPY | EVENTS | MYOCARDIAL-INFARCTION | CHOLESTEROL | DISEASE | PRAVASTATIN | STATINS | Single-Blind Method | Follow-Up Studies | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Systole | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Heart Failure - etiology | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Heart Failure - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Ischemia - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Heart failure | Placebos | Rosuvastatin | Dosage and administration | Drug therapy | Comparative analysis | Cardiovascular disease | Heart attacks | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Myocardial Ischemia | epidemiology | Pyrimidines | Heart Failure | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | complications | Fluorobenzenes | Hospitalization | etiology | statistics & numerical data | Sulfonamides | mortality | adverse effects | therapeutic use
Journal Article